Literature DB >> 7264626

Epidemiology of Parkinson's disease--an overview.

R J Marttila, U K Rinne.   

Abstract

Among the white races, the prevalence rates of Parkinson's disease range from 66 to 187 per 100,000 population, through without any obvious geographical pattern. A similar variation is found in the annual incidence rates with estimates from 5 to 24 per 100,000 population. The black races may be partially protected against the disease. Both sexes are probably equally affected by the disease. Parkinson's disease usually begins after the age of 50 years, and the risk of the disease steeply rises with advancing age. Parkinson's disease is often omitted in death certificates; mortality rates with Parkinson's disease as an underlying cause of death vary from 0.5 to 3.8 per 100,000. Levodopa treatment, by reducing the excess mortality accompanying the natural course of Parkinson's disease, may increase the number of patients living with this disease in the near future. Postencephalitic Parkinson's disease, developing as a sequel to lethargic encephalitis and accounting for some two thirds of parkinsonian cases shortly after the epidemic, has probably been a transient phase in the epidemiology of Parkinson's disease and is now disappearing. Data from epidemiological investigations have advanced our understanding of the cause of Parkinson's disease only to a small extent. No other characteristic than race has been found to influence the susceptibility to the disease. The environmental risks for Parkinson's disease have not been unequivocally demonstrated. Highly conflicting information is available as to the contribution of hereditary to the pathogenesis of Parkinson's disease. Seroepidemiological investigations have shown an increased antibody response against herpes simplex virus in parkinsonian patients, but attempts to detect herpes virus specific products or DNA sequences in the brain material have been unsuccessful.

Entities:  

Mesh:

Year:  1981        PMID: 7264626     DOI: 10.1007/BF01664011

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  39 in total

1.  Viral antibodies in serum and CSF of Parkinsonian patients and controls.

Authors:  T S Elizan; D L Madden; G R Noble; K L Herrmann; J Gardner; J Schwartz; H Smith; J L Sever; M D Yahr
Journal:  Arch Neurol       Date:  1979-09

2.  Occurrence of Parkinson's disease in black patients at Charity Hospital in New Orleans.

Authors:  R M Paddison; R P Griffith
Journal:  Neurology       Date:  1974-07       Impact factor: 9.910

3.  A clinical survey of parkinsonism in Iceland.

Authors:  K R Gudmundsson
Journal:  Acta Neurol Scand       Date:  1967       Impact factor: 3.209

4.  Mortality of patients with Parkinson's disease treated with levodopa.

Authors:  R J Marttila; U K Rinne; T Siirtola; V Sonninen
Journal:  J Neurol       Date:  1977-10-07       Impact factor: 4.849

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Epidemiology of Parkinson's disease in Finland.

Authors:  R J Marttila; U K Rinne
Journal:  Acta Neurol Scand       Date:  1976-02       Impact factor: 3.209

7.  Present morality in parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths.

Authors:  S G Diamond; C H Markham
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

8.  Cigarette smoking and Parkinson disease: 1. Comparison of cases with matched neighbors.

Authors:  R J Baumann; H D Jameson; H E McKean; D G Haack; L M Weisberg
Journal:  Neurology       Date:  1980-08       Impact factor: 9.910

9.  Levodopa in Parkinson disease: a long-term appraisal of mortality.

Authors:  C Joseph; J B Chassan; M L Koch
Journal:  Ann Neurol       Date:  1978-02       Impact factor: 10.422

10.  Smoking and Parkinson's disease.

Authors:  R J Marttila; U K Rinne
Journal:  Acta Neurol Scand       Date:  1980-11       Impact factor: 3.209

View more
  7 in total

Review 1.  Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Authors:  H M Bryson; R J Milne; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

Review 2.  Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.

Authors:  Rainer Knörle
Journal:  Neurotox Res       Date:  2017-09-06       Impact factor: 3.911

Review 3.  Diagnosis and treatment of Parkinson's disease in the elderly.

Authors:  J I Sage; M H Mark
Journal:  J Gen Intern Med       Date:  1994-10       Impact factor: 5.128

4.  Racial differences in the etiology of dementia and frequency of Alzheimer lesions in the brain.

Authors:  S M de la Monte; G M Hutchins; G W Moore
Journal:  J Natl Med Assoc       Date:  1989-06       Impact factor: 1.798

5.  An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain.

Authors:  C Pacheco; L G Aguayo; C Opazo
Journal:  Front Physiol       Date:  2012-07-26       Impact factor: 4.566

6.  The Demise of Poskanzer and Schwab's Influenza Theory on the Pathogenesis of Parkinson's Disease.

Authors:  Danny Estupinan; Sunina Nathoo; Michael S Okun
Journal:  Parkinsons Dis       Date:  2013-06-11

Review 7.  Metabolism and possible health effects of aluminum.

Authors:  P O Ganrot
Journal:  Environ Health Perspect       Date:  1986-03       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.